#Sweden #Gothenburg #Cereno Scientific #CS1 Treatment #PAH Patients

Cereno Scientific Reports Positive Safety Outcomes for CS1 Treatment in PAH

Cereno Scientific, a biotechnology company known for developing groundbreaking therapies for rare cardiovascular and pulmonary diseases, has revealed promising results from its Expanded Access Program (EAP) involving its lead drug candidate, CS1. This data sheds light on the safety and tolerability of CS1 following twelve months of treatment for patients suffering from Pulmonary Arterial Hypertension (PAH).

Overview of CS1 and PAH

Pulmonary Arterial Hypertension is a serious condition characterized by elevated blood pressure in the pulmonary arteries, often leading to right heart failure and premature death. Available treatments primarily focus on symptom management, meaning there is a critical need for therapies that can modify the disease and promote better long-term outcomes. Here is where CS1 comes into play.

CS1 is an orally administered histone deacetylase inhibitor (HDACi) designed to address the underlying mechanisms driving PAH. By targeting vascular remodeling, fibrosis, and inflammation, CS1 aims to offer a well-tolerated treatment option that can potentially change the disease trajectory.

Key Findings from the Expanded Access Program

The EAP included ten patients who previously completed the Phase IIa trial, allowing them to continue receiving CS1 through physician oversight. After twelve months, the outcomes highlighted a favorable safety and tolerability profile consistent with earlier Phase IIa results. Notably, there were no reported deaths or treatment discontinuations attributed to CS1. 60% of participants successfully completed the entire treatment duration.

However, two patients had to stop treatment due to atrial fibrillation events, which were assessed as unrelated to the drug. Additionally, one patient withdrew consent and another was lost to follow-up, leaving a solid base of participants who demonstrated the tolerability of the treatment over the long term.

Expert Insights

The results have been met with optimism from Cereno Scientific executives. Dr. Rahul Agrawal, the Chief Medical Officer, highlighted the critical nature of these findings, stating: "In PAH, existing therapies can pose safety risks, and we see a significant unmet need for safer alternatives. These results bolster our resolve to further develop CS1's potential."

Cereno’s CEO, Sten R. Sörensen, expressed confidence in CS1's role as a future treatment option for PAH, emphasizing that the backing of Phase II data illustrates the value and viability of the drug in addressing this unmet medical need.

Future Prospects

The EAP followed a successful Phase IIa trial, which documented the safety and efficacy signals of CS1 over a shorter, three-month period. The data obtained will contribute to the understanding of CS1 and its implications for treating PAH. Preparations are underway for a broader Phase IIb trial, set to begin patient enrollment in June 2026.

Through ongoing investigations, including advanced imaging studies aiming to utilize innovative technology, Cereno Scientific is working to provide further insights into how CS1 can better patient outcomes and potentially transform the standards for PAH treatment.

Closing Thoughts

Given its first-in-class potential and robust safety profile, Cereno Scientific's CS1 treatment could herald a new era for PAH therapies. For patients enduring the crushing reality of this condition, the prospect of a safer, disease-modifying treatment may not be far off.

For additional inquiries, you can reach out to Tove Bergenholt, Head of Investor Relations at Cereno Scientific, via email or phone.

About Cereno Scientific

Based in Gothenburg, Sweden, Cereno Scientific is dedicated to offering transformative drug candidates aimed at enhancing and extending patients' lives. With a strategic focus on rare cardiovascular and pulmonary diseases, the company is committed to developing effective and tolerable therapies that address substantial unmet needs.